At a Glance

Testosterone is the primary male sex hormone responsible for muscle development, bone density, mood, and sexual function. It's the most thoroughly researched and widely used hormone in men's optimization, with decades of clinical evidence supporting its safety when properly dosed and monitored under physician guidance.

What It Is

Testosterone is a naturally occurring steroid hormone produced primarily in the testes. It's essential for the development and maintenance of male characteristics and is available in multiple pharmaceutical formulations including injections, gels, patches, and pellets. Clinical-grade testosterone is one of the most studied compounds in medicine.

How It Works

Testosterone binds to androgen receptors throughout the body, triggering gene expression that increases protein synthesis, bone mineralization, and muscle mass. It influences mood and cognition through both genomic and non-genomic pathways. In the brain, it's converted to estradiol via aromatase, which is crucial for bone health and sexual function.

Key Benefits

  • Increases lean muscle mass and strength
  • Improves bone mineral density and fracture resistance
  • Enhances sexual function, libido, and erectile quality
  • Lifts mood, energy, and cognitive clarity
  • May improve metabolic health and insulin sensitivity

Who It's For

  • Men with clinically documented hypogonadism (low testosterone)
  • Middle-aged and older men experiencing age-related testosterone decline
  • Athletes and fitness enthusiasts seeking muscle and strength gains
  • Men reporting fatigue, low mood, or sexual dysfunction linked to low testosterone

Typical Use

Clinical doses range from 50–200 mg weekly via injection, or 4–10 grams of topical gel daily. Dosing is individualized based on serum testosterone levels, with typical targets of 400–700 ng/dL per Endocrine Society guidelines (mid-normal range; targeting 900 ng/dL routinely is supraphysiologic for many older men and increases risk of erythrocytosis and cardiovascular strain). TRT for confirmed hypogonadism is typically an indefinite (lifelong) therapy—not a time-limited trial. The Endocrine Society does not describe a “trial period”; rather, ongoing TRT is recommended with regular monitoring. ⚠️ CRITICAL FERTILITY WARNING: TRT suppresses the HPG axis, leading to marked reduction or complete absence of sperm (azoospermia) in the majority of men. Members who have not completed their family or who may consider future fertility MUST be warned. Recovery of spermatogenesis after TRT discontinuation is not guaranteed and can take 12–24+ months. Consider enclomiphene or HCG as alternatives if fertility preservation is needed.

Important Safety Information

  • Requires regular blood monitoring (testosterone, hematocrit, liver enzymes, PSA). Per Endocrine Society guidelines, TRT should be withheld or dose-adjusted if hematocrit exceeds 54%
  • Can increase red blood cell production, requiring phlebotomy in some cases
  • Potential for acne, male pattern baldness acceleration, and mood changes at high doses
  • Contraindicated in untreated prostate cancer AND male breast cancer (breast carcinoma in men is explicitly listed as a contraindication in the FDA testosterone prescribing label); relative caution in benign prostate enlargement

Global Regulatory Status

Note: Global regulatory consensus supports testosterone as a legitimate therapeutic agent for documented hypogonadism, though availability and formulation options vary by jurisdiction.

The Bottom Line

Testosterone is the safest and most effective hormone for men with documented deficiency. When dosed thoughtfully and monitored regularly, it delivers substantial benefits in strength, mood, and sexual function.

Update (August 2026): the TRAVERSE cardiovascular safety trial

TRAVERSE (New England Journal of Medicine, 2023) randomized 5,246 middle-aged and older men with hypogonadism and elevated cardiovascular risk to testosterone gel or placebo. Testosterone was noninferior to placebo for major adverse cardiac events — 7.0% versus 7.3%, hazard ratio 0.96 — answering the central cardiovascular safety question in the population studied. The same trial recorded more atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm, and a pre-specified sub-study found clinical fractures were more frequent with testosterone (3.50% versus 2.46%, hazard ratio 1.43) — a counterintuitive result worth knowing before framing testosterone as bone-protective.

What TRAVERSE does not show is benefit. It was a safety trial in men who already met criteria for hypogonadism. It does not support testosterone for men with normal levels, and it does not change the earlier finding from the Testosterone Trials that benefits in older men with low levels are real but modest and domain-specific. References: Lincoff 2023, PubMed 37326322; Snyder 2024 fracture sub-study, PubMed 38231621.

This guide is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement or medication.